Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according ...
Colon cancer used to be treated the same way for almost everyone. That’s no longer true. Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment ...
Survival following relapse appears to be shorter in patients with stage III colon cancer harboring KRAS exon 2 and BRAF V600E mutations regardless of microsatellite stability status. “We demonstrated ...
Association of GRP78 polymorphisms with response and TTP in patients with mCRC treated with FOLFOX/BV or XELOX/BV. Background: KRAS and possibly BRAF mutations are negative predictors for anti-EGFR ...
BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.
Among patients with KRAS G12C mutations, candidate primary resistance mutations were detected in many patients with colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), which may limit ...
Incyte, the Wilmington, Delaware-based biopharmaceutical company, will pair its investigational KRAS G12D inhibitor with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results